ArticleInternational ophthalmology2025
Posterior capsular opacification requiring Nd:YAG capsulotomy after ENOVA GF3 hydrophobic monofocal IOL implantation.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the incidence, timing, and clinical characteristics of posterior capsule opacification (PCO) and Nd:YAG laser capsulotomy after uneventful cataract surgery with implantation of the ENOVA GF3 single-piece hydrophobic acrylic intraocular lens (IOL).
methodsIn this retrospective study, the medical records of patients with a minimum of 6 months follow-up who underwent uncomplicated phacoemulsification with in-the-bag implantation of the ENOVA GF3 hydrophobic monofocal IOL between January 2022 and December 2024 were reviewed. Standardized phacoemulsification was performed by a single surgeon, including posterior capsule polishing and verification of capsulorhexis-optic overlap. Postoperative best-corrected visual acuity (BCVA), refractive outcomes, and slit-lamp findings were recorded. Nd:YAG capsulotomy was performed when BCVA declined to 20/50 or worse or when central PCO impaired visual function or fundus visualization. The primary outcomes were the rates of PCO and Nd:YAG capsulotomy and the time intervals from surgery to PCO detection and capsulotomy.
resultsA total of 151 eyes of 150 patients with mean age of 65.4±9.2 years were included. Significant improvement was observed in both uncorrected and corrected distance visual acuity at all postoperative visits (p 0.05). Postoperative refractive outcomes showed stability toward emmetropia with progressive reduction in spherical and cylindrical error (p 0.05). PCO developed in 5 eyes (3.3%). Of these, 3 cases (60%) were identified at postoperative month 1 and 2 cases (40%) at month 3. All PCO cases required Nd:YAG capsulotomy, performed at month 3 in 2 eyes (40%) and month 6 in 3 eyes (60%). No Nd:YAG-related complications were documented.
conclusionThe ENOVA GF3 single-piece hydrophobic acrylic IOL demonstrated a low 1-year incidence of PCO (3.3%) requiring Nd:YAG capsulotomy, which may be attributed to its hydrophobic acrylic material, sharp posterior optic edge, and stable in-the-bag positioning. These findings support the favorable posterior capsular performance and optical stability of the ENOVA GF3 IOL. Longerterm, comparative, and prospective studies are warranted to further assess modifiable factors influencing PCO development.
Indexed as
Identifiers
41417153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.